Compositions for the treatment of symptoms of inflammatory disorders may
include gamma-linolenic acid or dihomogammalinolenic acid, an inhibitor
of .DELTA..sup.5 desaturase, and optionally stearidonic acid or .omega.-3
arachidonic acid. Preferred formulations may be in the form of a good
tasting, preferably milk or fruit based drink, or a dried powder.
Compositions reduce inflammation and inhibit increase in serum
arachidonic acid associated with gamma-linolenic acid.